聚 ((乙烯基醇) 甲基乙烯烯酸接种基托桑基微粒和纳米颗粒作为抗生素药物输送系统
Corina-Lenuța Logigan1, Christelle Delaite2, Marcel Popa1,3,4
1Department of Natural and Synthetic Polymers, Faculty of Chemical Engineering and Environmental Protection "Cristofor Simionescu", "Gheorghe Asachi" Technical University of Iasi, Bld. Prof. Dr. Doc. Dimitrie Mangeron Street, No. 73, 700050 Iasi, Romania.
Polymers
|January 11, 2024
概括
化学修饰的素纳米颗粒 (NP) 已开发用于增强药物输送. 这些生物相容的NP显示了对封装和释放抗生素如利沃素和西普罗素的有希望的结果.
科学领域:
- 纳米技术和材料科学 纳米技术和材料科学
- 生物医学工程 生物医学工程
- 聚合物化学 聚合物化学
背景情况:
- 素 (CS) 是一种天然的多糖,具有药物输送潜力.
- 在中性/基本pH值下CS的水溶性较差限制了其应用.
- 微粒子和纳米粒子 (MP/NP) 为药物载体提供独特的特性.
研究的目的:
- 开发经过PEGA修饰的聚乙烯基醇甲基乙烯酸 (PEGA) 的CS MPs/NP.
- 为抗生素levfloxacin (LEV) 和ciprofloxacin (CIP) 创建一个响应pH的药物输送系统.
- 评估开发的MP/NP的物理化学特性,药物加载,释放和生物相容性.
主要方法:
- CS是用PEGA.化学修饰的.
- 用双重交联方法 (离子和共价) 在水/油乳液中制备MP/NP.
- 描述包括FT-IR,SEM,光散射和Zeta潜力分析.
- 对LEV和CIP进行了药物封装和释放研究.
- 通过细胞和血液安全测试评估了体外生物相容性.
主要成果:
- 成功合成了经过PEGA修改的CS MP/NP.
- 颗粒显示了pH取决于水的吸收.
- 对于LEV和CIP,观察到高的药物加载和释放效率.
- 开发的MP/NP显示出与细胞和血液的良好生物相容性.
结论:
- 经过PEGA修改的CS MP/NP是有效和安全的药物输送系统.
- 响应pH的性质和生物相容性突出了它们在生物医学应用中的潜力.
- 这项研究为开发用于抗生素输送的先进纳米载体提供了有前途的方法.
相关概念视频
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:11Oral Drug Delivery Systems: Delayed-Release Systems
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...